Tackling Rare Genetic Diseases with Diagonal Therapeutics

Today's episode is brought to you by scientist.com, the life science industry's leading R and D orchestration platform. Scientist.com gives researchers instant access to thousands of pre vetted suppliers, saving time, reducing costs, and accelerating innovation. Hi. I'm John Galliano, senior director of BioPharm Catalyst. Hello. I'm Chef, known as Chef Station, a twenty year vet in trading biotech stocks. And this is biotech bulls and breakthroughs. Biopharm Catalyst is not a registered investment advisory firm, and the views on this podcast are not intended to be financial advice. Guests on this podcast may hold the stocks discussed in personal or other investment accounts. This content is for informational purposes only and should not be considered investment advice. Always do your own research before making any investment decisions. If you find the information on this podcast useful and would like more catalyst information, BioPharm Catalyst is your premier resource for catalyst data for over 1,000 publicly traded biotech companies. We track clinical trial based catalysts, everything from IND filings to drug data releases for phase one, two, and three trials to regulatory decisions. Our Catalyst Calendars are updated as soon as the press release comes out, so you can be sure you have the most timely and accurate information to inform your biotech trading. All of our plans come with a seven day free trial and we frequently run discounts on our platform, So check out www.biopharmcatalyst.com to get started today. Good morning, good evening, or I should say good morning, good afternoon, good evening, depending on where you're joining us from. Welcome to another episode of biotech bulls and breakthroughs. For today's episode, we have a very unique guest on the line. We have Eric Duhaime from Diagonal Therapeutics. Actually, a privately held biotech company, specializing in, genetic diseases. And, Eric is the senior vice president of finance and corporate development. So, Eric, thank you so much for joining us. Welcome aboard, and I'll let you introduce yourself as well. Sure. Thanks. I appreciated you you having me on. Again, Eric Duham, senior vice president of finance and corporate development at Diagonal Therapeutics. I effectively oversee all of, general and administrative functions at Diagonal. I've been with the company for about three years. Prior to, joining Diagonal, I was the vice president of corporate development and finance at Goldfinch Bio, another privately held company. Most of my experience over, about twenty years of the biopharma industry has been in finance, corporate development, strategic marketing across a number of different small biotech companies, But most of the experience has been focused on rare genetic diseases and helping companies build markets for diseases where there's no, or, you know, really, poorly, tolerated treatments for patients with really severe diseases. Very cool. It's certainly a space that we are, familiar with ourselves. As you may or may not know, you know, Biopharm Catalyst, we have a ton of investors on our platform, who are screening various biotech companies, and, rare diseases is …